Navigation Links
Longs Drug Stores Corporation Reports Results for Fourth Quarter and Fiscal Year 2008
Date:3/5/2008

WALNUT CREEK, Calif., March 5 /PRNewswire-FirstCall/ -- Longs Drug Stores Corporation (NYSE: LDG) today reported preliminary income from continuing operations for the fourth quarter ended January 31, 2008, a 14-week period, of $37.8 million, or $1.00 per diluted share, including a $1.1 million after-tax net gain related to the planned disposition of seven California stores. Income from continuing operations for the fourth quarter ended January 25, 2007, a 13-week period, was $30.4 million, or $0.80 per diluted share, including a $1.4 million after-tax net charge for the asset impairment related to the planned disposition of seven California stores.

Total revenues of $1.45 billion for the 14 weeks ended January 31, 2008 were 11.0 percent higher than the $1.31 billion reported for the 13 weeks ended January 25, 2007. Total retail drug store sales for the quarter increased 9.1 percent and total pharmacy benefit services revenues increased 42.4 percent compared with last year.

The fiscal year ended January 31, 2008, included 53 weeks of operations compared with 52 weeks in the prior year with the additional week being the fourteenth week of the fourth quarter. The Company estimated that the additional week contributed approximately $0.05 per diluted share to income from continuing operations for the fourth quarter and full year ended January 31, 2008.

Income from continuing operations for the 53-week fiscal year ended January 31, 2008 was $98.9 million, or $2.59 per diluted share, including a $5.1 million after-tax net charge related to the planned disposition of seven California stores. Income from continuing operations for the 52-week fiscal year ended January 25, 2007 was $79.5 million, or $2.08 per diluted share, inclu
'/>"/>

SOURCE Longs Drug Stores Corporation
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine news :

1. Longs Drug Stores Corporation Declares Cash Dividend on Common Shares
2. Treating oft ignored non-cancer health issues after cancer diagnosis prolongs survival
3. Thalidomide Added to Standard Therapy Prolongs Overall Survival in Newly Diagnosed Multiple Myeloma Patients Over Age 75
4. Longs Drugs Plans to Become the First Retailer in Hawaii With Walk-in Medical Clinics
5. New chemotherapy regimen prolongs survival in difficult-to-treat childhood brainstem gliomas
6. Longs Drugs Announces Immunization Program for the 2007/2008 Flu Season
7. MinuteClinic Hits 500th Clinic Mark; New Locations Open in Dallas, Los Angeles and Orlando CVS/pharmacy Stores
8. China Nepstar Chain Drugstore to Acquire 68 Drugstores from Ningbo New Century Medical Ltd.
9. New Water Purification Product from Reliance Products and Procter & Gamble now Available in Retail Stores
10. Mylan Restores Availability of Generic Levothyroxine in Florida
11. Deli Chef Tri-Bean Salad Recalled From Some Kroger Stores
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Chinese-American Women & Korean-American Women at Highest Risk for Developing Diabetes During Pregnancy 2Chinese-American Women & Korean-American Women at Highest Risk for Developing Diabetes During Pregnancy 3Chinese-American Women & Korean-American Women at Highest Risk for Developing Diabetes During Pregnancy 4Boston Scientific Announces Pricing of $2 Billion of Senior Notes 2Boston Scientific Announces Pricing of $2 Billion of Senior Notes 3Federal Judge Rejects GlaxoSmithKline's Claims of Privilege 2Circadiance Launches NEW Zzzephyr Seal 28TM 29 for Its SleepWeaver 28TM 29 ADVANCE Mask Now Available in Three Colors 60056 1Circadiance Launches NEW Zzzephyr Seal 28TM 29 for Its SleepWeaver 28TM 29 ADVANCE Mask Now Available in Three Colors 60056 2STAAR Surgical Collamer 28R 29 Accommodating Study Team Reports First Phase Assessments at AAO 60052 1STAAR Surgical Collamer 28R 29 Accommodating Study Team Reports First Phase Assessments at AAO 60052 2STAAR Surgical Collamer 28R 29 Accommodating Study Team Reports First Phase Assessments at AAO 60052 3STAAR Surgical Collamer 28R 29 Accommodating Study Team Reports First Phase Assessments at AAO 60052 4STAAR Surgical Collamer 28R 29 Accommodating Study Team Reports First Phase Assessments at AAO 60052 5STAAR Surgical Collamer 28R 29 Accommodating Study Team Reports First Phase Assessments at AAO 60052 6Pharmalink AB Receives Patent for Nefecon 28R 29 Principle 5674 1Pharmalink AB Receives Patent for Nefecon 28R 29 Principle 5674 2Pharmalink AB Receives Patent for Nefecon 28R 29 Principle 5674 3